Capmatinib, a highly selective MET inhibitor, has demonstrated robust and durable systemic efficacy in patients with advanced METex14-mutated NSCLC, establishing its role as a key component of targeted therapy [3]. Here, MET is linked to non-small cell lung carcinoma.